Revvity (NYSE:RVTY) Q4 2025 Earnings call February 02, 2026 08:00 AM ET Company ParticipantsBrandon Couillard - Managing DirectorDan Arias - Managing DirectorDan Leonard - Managing DirectorLuke Sergott - Director for Healthcare Equity ResearchMax Krakowiak - SVP and CFOPrahlad Singh - President and CEOSteve Willoughby - SVP of Investor RelationsTycho Peterson - Managing DirectorVijay Kumar - Senior Managing DirectorConference Call ParticipantsAndrew Cooper - Equity Research AnalystCatherine Schulte - Senior ...

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $772 million, resulting in 4% organic growth, with a full year revenue of $2.86 billion, reflecting 3% organic growth [20][21] - Adjusted EPS for the fourth quarter was $1.70, exceeding guidance, while full year adjusted EPS was $5.06, representing a 3% year-over-year growth [9][23] - Adjusted operating margins for the fourth quarter were 29.7%, down 60 basis points year-over-year, while full year adjusted operating margins were 27.1%, down 120 basis points year-over-year [21][24] Business Line Data and Key Metrics Changes - The diagnostics segment achieved 7% organic growth in the fourth quarter, with full year organic growth of 4%, driven by strong performance in immunodiagnostics and reproductive health [6][27] - The life sciences segment remained flat year-over-year in organic growth for the fourth quarter, with full year organic growth also at 2%, impacted by low single-digit declines in academic and government sales [6][26] - Signals software business grew in the high teens organically for the full year, with a nearly 40% ARR growth compared to last year [26] Market Data and Key Metrics Changes - Geographically, the company experienced flat performance in both the Americas and APAC, while Europe saw double-digit growth [25] - For the full year, the Americas grew low single digits, Europe grew high single digits, and APAC declined in the low single digits [25] Company Strategy and Development Direction - The company plans to reinvest a portion of operational upside back into the business, focusing on employee support and capital deployment opportunities [10][19] - The acquisition of ACD/Labs is expected to contribute over $20 million in total revenue, adding approximately 75 basis points to overall revenue growth [12][30] - The introduction of the AI models-as-a-service platform, Signals Synthetica, is aimed at enhancing drug development processes [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery of end markets, reiterating a 2%-3% organic growth outlook for 2026 [11][29] - The company acknowledged recent positive trends in pharma and biotech funding, but remains prudent in its initial outlook due to ongoing market uncertainties [10][20] - Management highlighted the importance of maintaining a disciplined approach to capital deployment while navigating a fluid end market and policy environment [10][19] Other Important Information - The company repurchased over $800 million worth of shares in 2025, reducing the share count by 8.5 million shares [9][10] - Free cash flow for the fourth quarter was $162 million, resulting in 84% conversion of adjusted net income, with full year free cash flow at $515 million [24] Q&A Session Summary Question: Insights on the 2%-3% organic growth guidance - Management acknowledged positive signs in end markets since September but maintained the conservative guidance to allow for potential upside as the year unfolds [39][40] Question: Factors driving strength in life sciences instruments and reagents - Management indicated that improvements in preclinical spending and ongoing demand development are key drivers, with a focus on maintaining market share [45][46] Question: Timing and trajectory of new software product launches - Management confirmed that the Signals business is in a significant new product introduction phase, with expectations for growth rates to accelerate over the coming years [49][50] Question: Performance within pharma biotech and order trends - Management noted cautious optimism in order trends, with improvements attributed to greater clarity in the policy and regulatory environment [61][62] Question: Outlook for diagnostics business and potential upside - Management highlighted strong performance in newborn screening and immunodiagnostics, suggesting potential for upside in diagnostics for 2026 [65][66]

分组1 - Revvity (RVTY) reported quarterly earnings of $1.7 per share, exceeding the Zacks Consensus Estimate of $1.63 per share, and up from $1.42 per share a year ago, representing an earnings surprise of +4.29% [1] - The company posted revenues of $772.06 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.02%, and an increase from $729.37 million year-over-year [2] - Revvity has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 12.5% since the beginning of the year, compared to the S&P 500's gain of 1.4% [3] - The current consensus EPS estimate for the upcoming quarter is $1.11 on revenues of $679.95 million, and for the current fiscal year, it is $5.32 on revenues of $2.94 billion [7] - The Zacks Industry Rank indicates that the Medical Services sector is currently in the bottom 27% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Fourth Quarter 2025 Earnings February 2, 2026 Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "be ...

FOR IMMEDIATE RELEASE February 2, 2026 Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025 WALTHAM, Mass. -- Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income fr ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same perio ...

Core Insights - Revvity, Inc. (RVTY) is expected to report its fourth-quarter 2025 results on February 2, with a revenue estimate of $767.2 million, reflecting a 5.2% year-over-year increase, while earnings per share are projected at $1.55, indicating a 9.2% decline from the previous year [1][4][11] Group 1: Company Performance - The company has shown a consistent ability to exceed earnings estimates, with an average surprise of 4.16% over the last four quarters, including a 3.51% surprise in the last reported quarter [1][4] - Revvity's Life Sciences segment is anticipated to perform steadily, benefiting from software growth and early signs of improved customer activity, while the Diagnostics segment faces challenges due to reimbursement issues in China [2][11] - The Life Sciences segment's revenue is estimated at $376.2 million, representing an 11.9% year-over-year increase, while the Diagnostics segment's revenue is projected at $385.5 million, down 1.9% year-over-year [9][14] Group 2: Segment Analysis - In the Life Sciences segment, the Signals software business is expected to continue driving growth, having achieved 20% organic growth in the previous quarter, supported by strong SaaS adoption and high annual recurring revenue (ARR) growth [7][8] - The Diagnostics segment is expected to show mixed results, with strong demand outside China but ongoing reimbursement-related pressures in the Chinese market, where immunodiagnostics demand is projected to decline over 20% [12][13] Group 3: Operational Factors - Seasonal strength is expected to support fourth-quarter results, driven by higher software revenues and modest improvements in instrument volumes, despite ongoing pressures in the academic and government sectors [5][6] - Strategic partnerships, such as the collaboration with Genomics England, are anticipated to contribute positively to revenues, although near-term financial impacts may be limited [16] - The company is expected to maintain strong margins in the fourth quarter due to seasonal volume leverage, disciplined expense management, and ongoing share repurchase activities [17]

At Revvity, "impossible†is inspiration, and "can't be done†is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. WALTHAM, Mass.--(BUSINESS WIRE) ...

Core Insights - The presentation is led by Revvity's CEO, Prahlad Singh, who highlights the company's progress over the past year [1] - Revvity has undergone a portfolio transformation, evolving from an industrial company with a focus on analytical services, small molecule preclinical life sciences, and diagnostics [3] Financial Overview - The financial figures and growth rates discussed are based on guidance from the 3Q earnings call dated October 27, 2025 [2]

Revvity (NYSE:RVTY) FY Conference Summary Company Overview - Revvity is a $2.8 billion company, with revenue split roughly equally between life sciences and diagnostics segments [4] - The company has undergone a portfolio transformation, moving from a legacy industrial company to a focus on high-growth life sciences and diagnostics [2][3] Key Financial Metrics - Approximately 85% of revenue is recurring, derived from consumables, assets, services, and software [4] - Life sciences solutions have a five-year average organic growth rate of high single digits and operating margins above 30% [5] - Diagnostics revenue is about $1.4 billion, with a similar growth rate and operating margins around 25% [6] Strategic Initiatives - Revvity aims to be a key player in the drug development lifecycle, providing comprehensive solutions from early discovery to commercialization [9] - The company has launched AI initiatives, including Transcribe AI, which improves workflow speed by 40% for clinical lab customers [10][11] - A partnership with Eli Lilly aims to accelerate AI-enabled drug discovery through the Signals Synthetica platform [11][12] Market Dynamics - The life sciences segment is primarily focused on pharma and biotech, with 75% of customers in these sectors [5] - The diagnostics segment focuses on immunodiagnostics (60% of revenue) and reproductive health (40%) [6] - The company has seen a significant increase in immunodiagnostics revenue from the Americas, which has doubled from 10% to 20% [14] Growth Outlook - For 2026, Revvity expects 2%-3% organic growth, with high single-digit adjusted EPS growth [19][20] - The company anticipates double-digit growth in immunodiagnostics and Signals Software, with mid-single-digit growth in life sciences solutions and reproductive health [20] - The operational excellence initiatives aim for a 28% adjusted operating margin by 2026, with a focus on cost reductions and efficiency improvements [19] Partnerships and Collaborations - Revvity has formed strategic partnerships with Genomics England and Sanofi, focusing on large-scale genomic screening and pediatric disease screening [15][16][46] - The company is exploring opportunities for partnerships in AI and genomics, although specific details are not yet public [54] Challenges and Risks - The company faces headwinds in the Chinese market, particularly in immunodiagnostics, but expects growth to return in the second half of 2026 [50] - The overall market conditions and funding trends in biotech are seen as positive indicators for Revvity's growth [33][58] Conclusion - Revvity is positioned as an innovative life sciences and diagnostics company with a transformed portfolio and a focus on operational excellence, aiming for significant growth and margin expansion in the coming years [21][22]